✦ LIBER ✦

Soluble fas ligand in natural killer cell lymphoma

✍ Scribed by Murayama, Tohru; Koizumi, Tamio; Das, Hiranmoy; Kobayashi, Yukio; Kajimoto, Kazuyoshi; Sugimoto, Takeshi; Imoto, Shion; Nishimura, Ryuichiro; Nakagawa, Toshitaro

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 54 KB
Volume: 62
Category: Article
ISSN: 0361-8609
DOI: 10.1002/(sici)1096-8652(199912)62:4<253::aid-ajh11>3.0.co;2-h

No coin nor oath required. For personal study only.

✦ Synopsis

We measured serum soluble Fas ligand (sFasL) in a patient with natural killer cell lymphoma, and investigated relationship between sFasL and liver dysfunction. An elevated level of sFasL was decreased after local radiation therapy, and liver function improved. When lymphoma relapsed, liver dysfunction reappeared and the level of sFasL increased parallelly. Lymphoma cells expressed mRNA of FasL. This suggested that this liver dysfunction was induced by some remote effectors, and sFasL was one of candidates of these effectors. Am.

📜 SIMILAR VOLUMES

Expression of Fas and Fas ligand in cuta

Expression of Fas and Fas ligand in cutaneous B-cell lymphomas

✍ Zoi-Toli, Ourania; Meijer, Chris J. L. M.; Oudejans, Joost J.; de Vries, Els; va 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 2 views

Primary cutaneous B-cell lymphomas (CBCLs) represent a rare, but distinct group of B-cell neoplasms with a different clinical behaviour to B-cell lymphomas secondarily involving the skin. Fas-Fas ligand (Fasl) expression was investigated in a group of primary and secondary CBCLs to gain an insight i

Soluble Fas (APO-1, CD95) and soluble Fa

Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases

✍ Kazuhisa Nozawa; Nobuhiko Kayagaki; Yoshiaki Tokano; Hideo Yagita; Ko Okumura; H 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

Elevation of soluble Fas and soluble Fas

Elevation of soluble Fas and soluble Fas ligand in reactive macrophage activation syndromes

✍ Emmenegger, U.; Zehnder, R.; Frey, U.; Reimers, A.; Spaeth, P.J.; Neftel, K.A. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 2 views

Derailed T-cell activation can give rise to life-threatening macrophage activation, the final common pathway of the different forms of reactive macrophage activation syndromes (rMAS). Besides inappropriate activation of the immune system, impaired termination of immune responses might be another mec

Natural killer cell lymphoma/leukemia: p

Natural killer cell lymphoma/leukemia: pathology and treatment

✍ Y. L. Kwong; Alexander C. L. Chan; Raymond H. S. Liang 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 273 KB 👁 2 views

Malignancies arising from cells of putative natural killer (NK) cell origin have increasingly been recognized as distinct clinicopathological entities. These malignancies are marked by tumour cells with NK cell characteristics, including the immunophenotype of CD2 + , surface CD3 , cytoplasmic CD3 +

Low natural killer cell activity in pati

Low natural killer cell activity in patients with malignant lymphoma

✍ Thomas Tursz; Marie-Christine Dokhelar; Marc Lipinski; Jean-Louis Amiel 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

T-cell lymphoma associated with natural

T-cell lymphoma associated with natural killer-like T-cell reaction

✍ Sun, Tsieh; Susin, Myron; Brody, Judith; Tack, Kevin; Marsh, Jonathan; Teichberg 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 342 KB 👁 2 views

We report a case of T-cell lymphoma showing in the peripheral blood (PB) exclusively T-lymphocytes with suppresser T-cell preponderance and a high percentage of natural killer (NK) marker positive cells by flow cytometry. A T-cell receptor (TCR) gene analysis of the PB leukocytes demonstrated rearra